Luma reports positive results from clinical trials

Luma reports positive results from clinical trials

Luma is a Rosenman Founder’s Pledge company.

Luma Therapeutics, a company dedicated to eradicating suffering from inflammatory skin disease, today announced positive results from three clinical studies evaluating in-home treatment of patients with plaque psoriasis. Findings from the studies, which assessed the company’s FDA-cleared illuvinate™ System, were presented during the annual meeting of the American Academy of Dermatology Annual meeting in Washington, D.C.

The results of the third study, presented by Tina Bhutani, M.D., of the UCSF Medical Center in San Francisco, Calif., demonstrated significant improvement in symptoms and appearance for plaques treated with illuvinate, with healing that was maintained eight weeks following treatment.

The multi-site study measured clinical outcomes from 52 target psoriasis plaques in 26 patients, with an untreated plaque on each patient serving as the control. In the study, Target Plaque Assessment (TPA) score was assessed at the beginning of the study and over a period of six weeks while using illuvinate. This score included assessments of scale, redness and thickness of plaques. Findings showed a 66% reduction in TPA score at six weeks for plaques treated with illuvinate compared with a 15% reduction for untreated plaques. At 14 weeks (eight weeks following treatment), results showed a 70% reduction in TPA score, suggesting a therapeutic effect sustained beyond the treatment period. Nearly one-third of patients had complete clearance of plaque at 14 weeks.

“These data suggest that illuvinate provides Goeckerman-like healing for patients with plaque psoriasis, which continues even beyond the treatment period,” said Dr. Bhutani. “I believe illuvinate offers an exciting new prospect for many patients looking for an alternative to biologics and creams.”

“Psoriasis is a challenging condition to manage, and many patients feel disheartened by the inability to find a treatment option that works and provides lasting long relief,” said Dr. Jeffrey Sugarman, M.D., Ph.D., of Redwood Family Dermatology who served as the principal investigator of the study. “I have been impressed by the results, and particularly the durability of results, that I have seen in patients who have used the system.”

“As a psoriasis sufferer myself, I know the frustration these patients feel with the treatment options currently available to them,” said founder and CEO Evan Anderson. “We are pleased that the positive results of these studies show illuvinate’s innovative light therapy system delivers significant benefit including sustained, durable healing, suggesting that illuvinate has the potential to improve quality of life for these patients.”

About illuvinate™

The FDA-cleared illuvinate System is an innovative treatment designed to provide lasting relief from psoriasis symptoms. Inspired by the Goeckerman Regimen, a 100-year-old proven therapy that results in long periods of remission lasting over a year.1 However this treatment is only available at a handful of specialized centers and often requires multiple day-long clinic visits over a period of weeks, creating barriers to widespread adoption. Luma Therapeutics has redesigned the key elements of the Goeckerman Regimen to make it available to patients in their own home.

Illuvinate has been demonstrated to reduce local inflammation, rehydrate the skin and restore normal skin cells. The system includes patented hydrating technology, a narrowband UV LED light system, and a proprietary app-based dosing algorithm. The therapy is applied for just minutes each day over a six-week period from the comfort and convenience of home. The system can now be prescribed either by a dermatologist or via Luma’s telehealth provider, HealthLens.

About Luma Therapeutics

Based in Silicon Valley, Luma Therapeutics is a privately held medical technology company committed to developing innovative and convenient therapies for the millions of people around the world suffering from inflammatory skin disease. In collaboration with Mayo Clinic, Luma Therapeutics developed the FDA-cleared illuvinate™ System to offer patients with psoriasis an effective treatment option that can be used at home. The company has also been supported by StartX accelerator and the Rosenman Institute at QB3. For more information visit www.lumatherapeutics.com.

From Business Wire